Regimen | Number (%) | P value | Duration* (months) | P value | ||
---|---|---|---|---|---|---|
Linezolid group | Control group | Linezolid group | Control group | |||
LZD | 164 (100.0) | 0 (0.0) | < 0.001 | 15.8(15.0,16.6) | -- | -- |
AMK | 146 (89.0) | 162 (94.2) | 0.087 | 15.6(15.2,16.5) | 18.1(18.0,19.0) | < 0.01 |
CLR/AZM | 133 (81.1) | 152 (88.4) | 0.063 | 15.9(15.0,18.5) | 18.0(17.8,19.0) | < 0.01 |
CFZ | 74 (45.1) | 95(55.2) | 0.064 | 16.5(16.1,18.0) | 18.0(18.0,19.0) | < 0.01 |
FOX | 61 (37.2) | 79 (45.9) | 0.104 | 2.6(2.3,2.6) | 3.0(2.5,3.0) | < 0.01 |
IMP | 8 (4.9) | 11 (6.4) | 0.547 | 2.3(2.2,2.3) | 2.6(2.5,3.0) | 0.02 |
DOX | 20(12.2) | 28 (16.3) | 0.275 | 16.5(16.2,17.0) | 17.5(17.5,18.4) | < 0.01 |
MFX | 6 (3.7) | 9 (5.2) | 0.485 | 16.9(16.0,16.73) | 18.0(17.5,19.5) | < 0.01 |